Teva Pharmaceutical Industries Ltd. TEVA
39.19
(1.03)
(2.56%)
as of 25 Sep
- Market cap
- $46.9B
- P/E
- 62.2×
Follow TEVA
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
53.78 | 21.99 | 25.17 | 32.06 |
+8 more quarters Free account |
P/S ratio |
2.28 | 2.01 | 2.07 | 1.38 | |
P/FCF ratio |
28.17 | 28.28 | 30.23 | 37.61 | |
P/Operating CF |
96.03 | (870.47) | 30.86 | 62.79 | |
P/B ratio |
5.09 | 4.23 | 4.52 | 3.19 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.03 | 2.75 | 2.84 | 2.25 | |
EV/EBITDA |
20.91 | 14.52 | 15.50 | 10.07 | |
EV/Operating CF |
27.61 | 27.83 | 29.71 | 35.42 | |
EV/FCF |
37.41 | 38.75 | 41.44 | 61.29 | |
Quick Ratio |
0.46 | 0.53 | 0.54 | 0.52 | |
Current Ratio |
0.88 | 1.01 | 1.04 | 1.11 | |
Net Debt/EBITDA |
82.40 | 14.46 | 40.40 | 12.91 | |
Debt/Assets |
41.63% | 41.53% | 41.24% | 42.13% | |
Debt/Equity |
2.14 | 2.02 | 2.12 | 2.31 | |
Asset Turnover |
0.43 | 0.44 | 0.43 | 0.41 | |
Operating CF/Net income |
(0.71) | (0.11) | 2.41 | 0.85 | |
Capex/Depreciation |
(0.42) | (0.53) | (0.55) | (0.52) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
23.42% | 5.58% | 5.65% | 5.71% | |
Selling, General and Administrative Expense of Revenue |
24.96% | 25.11% | 23.82% | 21.72% | |
Intangible Assets out of Total Assets |
0.48 | 0.49 | 0.49 | 0.50 | |
Share Based Compensation of Revenue |
0.97% | 1.08% | 1.08% | 0.76% | |
Graham Net Nets |
(0.46) | (0.52) | (0.53) | (0.86) | |
Graham Number |
9.72 | 14.82 | 13.89 | 9.47 | |
Earnings Yield |
1.86% | 4.55% | 3.97% | 3.12% | |
Free Cash Flow Yield |
3.55% | 3.54% | 3.31% | 2.66% | |
Revenue per Share |
3.56 | 3.44 | 4.11 | 3.91 | |
Operating CF per Share |
0.35 | (0.03) | 1.01 | 0.32 | |
Capex per Share |
(0.09) | (0.11) | (0.12) | (0.11) | |
Free Cash Flow per Share |
0.27 | (0.14) | 0.89 | 0.21 | |
Cash per Share |
3.14 | 3.24 | 3.11 | 1.92 | |
Shareholders Equity per Share |
6.66 | 7.12 | 6.91 | 6.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.66 | 7.12 | 6.91 | 6.32 | |
Free Cash Flow |
310.00 | (166.00) | 1,016.00 | 241.00 | |
Working Capital |
(1,886.00) | 178.00 | 490.00 | 1,245.00 | |
Capital Expenditures |
(101.00) | (126.00) | (142.00) | (128.00) | |
Net Current Asset Value |
(18,340.00) | (18,099.00) | (18,888.00) | (19,866.00) | |
EV/EBIT |
34.52 | 20.84 | 22.70 | 13.78 | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 | |
Net Profit Margin |
(13.91%) | 9.27% | 10.21% | 9.67% | |
Price to Operating Income |
26.00 | 15.21 | 16.56 | 8.46 | |
| Other line items | |||||
Average Receivables |
3,528.50 | 3,388.50 | 3,384.00 | 3,636.00 | |
Average Payables |
2,609.50 | 2,443.00 | 2,367.00 | 2,363.00 | |
Average Inventory |
3,359.00 | 3,211.50 | 3,093.00 | 3,641.00 | |
Average Assets |
39,994.00 | 39,227.50 | 40,037.00 | 40,807.00 | |
Average Common Equity |
7,295.00 | 7,250.50 | 6,647.00 | 6,819.00 |
Columns are period end dates